Urologix Reports 48% Increase in Sequential Revenue for Fiscal 2012 Second Quarter

• $4.7 million in revenue, 40% quarterly revenue growth year over year
• Positive cash flow in the quarter of $17 thousand
• $2 million credit facility established

MINNEAPOLIS, Jan. 24, 2012 (GLOBE NEWSWIRE) -- Urologix®, Inc. (Nasdaq:), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today reported financial results for its fiscal second quarter ended December 31, 2011.

Second quarter fiscal year 2012 revenue totaled $4.7 million. The 48% sequential growth in revenue was attributable to 11% of sequential growth in the Company's Cooled ThermoTherapy™ (CTT) base business and the additional benefit from the first full quarter of selling the Prostiva® Radio Frequency (RF) Therapy product following the license acquisition on September 6, 2011. Revenue grew 40% year over year, driven by the incremental contribution of Prostiva product revenue.

As of December 31, 2011, the Company's cash balance was $1.6 million. The Company generated $17 thousand of cash in the second fiscal quarter ended December 31, 2011 compared to cash utilization of $413 thousand in the same period last year. The cash performance is a result in part of beneficial payment terms on Prostiva product inventory and the timing of royalty payments. Payments for approximately $1.3 million of Prostiva product purchased during the second quarter of fiscal year 2012 were deferred as a result of 270 day terms negotiated as part of the license agreement. On January 11, 2012, the Company also closed on a credit facility for $2 million with Silicon Valley Bank to provide additional liquidity for the ongoing integration of the Prostiva business. 

"The second quarter marks the first full quarter since we announced the acquisition of the license for the Prostiva RF Therapy product line. We are encouraged with the contribution of the Prostiva product and are pleased with the first sequential growth in Cooled ThermoTherapy in four quarters. Our solid performance with both products in our portfolio this quarter demonstrates the benefit of our leading market share position supported by our recently expanded sales force," stated Stryker Warren Jr., CEO. "We are also encouraged by our market development initiatives to increase awareness among urologists and patients of Urologix's non-surgical alternatives to drug therapy and by the early success of our patient education seminars."

Gross profit for the second quarter of fiscal year 2012 was $2.3 million, or 49% of revenue, compared to $1.4 million, or 45% of revenue, in the first quarter of fiscal year 2012 and $1.8 million, or 56% of revenue, in the second quarter of fiscal year 2011. Gross margin for the second quarter of fiscal year 2012 was lower than the prior year quarter due to the 45% gross margin on the Prostiva product line, which included $86 thousand of non-cash charges, or 2% of revenue, primarily for the amortization of intangible assets. In addition, there was a negative impact from the product mix in the CTT business as well as slightly lower production volumes. 

Total operating expense in the second quarter of fiscal year 2012 of $3.2 million increased 24% year-over-year driven primarily by the expansion of the direct sales force that occurred with the acquisition of the Prostiva product line. General and administrative expenses in the second quarter of fiscal year 2012 also included $157 thousand of one-time legal and accounting costs related to the acquisition, as well as the initiation cost of the credit facility.

For the second quarter of fiscal year 2012, Urologix reported a net loss of $1.1 million, or $0.08 per diluted share, compared to a net loss of $712 thousand, or $0.05 per diluted share, in the second quarter of fiscal year 2011. The net loss in the second quarter of fiscal year 2012 was adversely affected by the numerous Prostiva transaction related items described above, including $213 thousand of imputed interest expense on deferred acquisition payments.

Outlook

The Company continues to expect that revenue for full year fiscal 2012 will be in the range of $18 to $20 million.

Earnings Call Information

Urologix will host a conference call with the financial community to discuss fiscal 2012 second quarter results on Tuesday, January 24, 2012 at 4:00 p.m. Central Standard Time. To listen to the call, please dial 1-866-510-0711 and enter the Participant Passcode 86583253 at least 10 minutes prior to the call. A live webcast of the call will be available through the investor relations section of the Company's website at and available for replay approximately two hours after the completion of the call.

About Urologix

Urologix, Inc., based in Minneapolis, develops, manufactures, markets and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH).  Urologix' Cooled ThermoTherapy™ produces targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort.  The Cooled ThermoTherapy™ product line includes the CoolWave® and Targis® Control Units and the CTC Advance® and Targis® catheter families.  The Prostiva® RF Therapy System distributed by Urologix delivers radio frequency energy directly into the prostate destroying prostate tissue, reducing constriction of the urethra, and thereby relieving BPH voiding symptoms.  Both of these products provide safe, effective and lasting relief of the symptoms and obstruction due to BPH. Prostiva® is a registered trademark of Medtronic, Inc., used under license.  All other trademarks are the property of Urologix.